CURLIM Awarded for its Innovative Research

We are proud to announce that CURLIM has been awarded as part of the 2024–2025 State Innovation Challenge, joining 147 projects supported by the French government under #France2030.

This recognition marks a major milestone for CURLIM

It reflects our determination to accelerate the development of innovative treatments for Charcot-Marie-Tooth disease (CMT).
With CLM001, our innovative nanomedicine, we aim to target the root mechanisms of the disease and pave the way for new therapeutic perspectives.

The I-Lab award, which recognizes the most innovative technology companies, reinforces our mission to turn scientific innovation into therapeutic solutions.
Over the years, I-Lab has stood as a label of excellence and a recognized accelerator for high-potential startups.

This award confirms CURLIM’s position among France’s most promising biotech innovators.

A sincere thank you to the Government, Bpi France, and ADEME for their trust and support.

Our gratitude also goes to our operational team : Frédéric Elustondo, William Moret, Léa Juillard-Condat, Dzmitry Siamashchuk and our co-founders : Franck Sturtz, Vincent Sol, Alexis Desmoulière, Laurent Richebourg for their commitment, expertise, and determination in driving this ambitious project forward.